Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0,21%
1 091,51
-2,30
-0,21%
—1 093,811 096,521 100,221 091,51——
SIXC
Communications
SIXC
Communications
SIXC
+0,22%
610,11
+1,34
+0,22%
—608,77608,77612,97608,77——
SIXE
Energy
SIXE
Energy
SIXE
-1,34%
1 237,98
-16,83
-1,34%
—1 254,811 253,011 253,871 226,33——
SIXI
Industrials
SIXI
Industrials
SIXI
-0,93%
1 744,71
-16,40
-0,93%
—1 761,111 764,271 766,881 744,71——
SIXM
Financials
SIXM
Financials
SIXM
-0,37%
640,18
-2,40
-0,37%
—642,58644,87648,48640,18——
SIXR
Staples
SIXR
Staples
SIXR
-0,18%
849,58
-1,55
-0,18%
—851,13855,66858,75845,56——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0,23%
217,48
-0,50
-0,23%
—217,98217,98218,65216,88——
SIXT
Technology
SIXT
Technology
SIXT
+1,52%
3 260,69
+48,86
+1,52%
—3 211,833 227,213 268,383 226,55——
SIXU
Utilities
SIXU
Utilities
SIXU
-0,69%
942,45
-6,53
-0,69%
—948,98948,58957,83941,97——
SIXV
Health care
SIXV
Health care
SIXV
-0,52%
1 466,80
-7,72
-0,52%
—1 474,521 479,031 481,041 466,80——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0,22%
2 397,50
+5,38
+0,22%
—2 392,122 396,952 421,222 382,32——
NOV:FRA
Novo Nordisk A/S
€36,42
+5,69%
(+1,96) 1D
30 Apr., 22:00:00 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for NOV...
Open
€34,56
High
€36,50
Low
€34,04
Mkt. cap
149,89 mjd
Avg. vol.
21,40 k
Volume
11,43 k
52-wk high
€71,54
52-wk low
€30,29
No. of employees
69 k
News stories
From sources across the web
Profile
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28.1% of its shares and a majority of its voting shares. Novo Nordisk manufactures and markets pharmaceutical products and services, specifically diabetes and obesity medications and devices. Novo Nordisk employs more than 48,000 people globally, and markets its products in 168 countries. The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s. Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations. The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was named the most sustainable company in the world by the business magazine Corporate Knights, while spin-off company Novozymes was named fourth. It is a leader in the FTSE4Good Index, and the only European company in the top ten. Novo Nordisk is the largest pharmaceutical company in Denmark. Wikipedia
About Novo Nordisk A/S
CEOMaziar Mike Doustdar
Employees69,2 k
Founded21 Des. 1923
HeadquartersBagsværd, Capital Region of Denmark, Denemarke
SectorPharmaceutical industry
Websitenovonordisk.com
Previous reportsAll values in DKK
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in DKK
Mrt. 2025
Jun. 2025
Sep. 2025
Des. 2025
Revenue
78,09 mjd
76,86 mjd
74,98 mjd
79,14 mjd
Cost of goods sold
12,89 mjd
12,85 mjd
14,47 mjd
14,17 mjd
Cost of revenue
12,89 mjd
12,85 mjd
14,47 mjd
14,17 mjd
Research and development expenses
10,31 mjd
11,69 mjd
11,49 mjd
12,67 mjd
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
16,11 mjd
18,85 mjd
15,76 mjd
17,14 mjd
Operating expense
26,41 mjd
30,56 mjd
27,25 mjd
29,73 mjd
Total operating expenses
39,30 mjd
43,41 mjd
41,72 mjd
43,90 mjd
Operating income
38,79 mjd
33,45 mjd
33,25 mjd
35,24 mjd
Other non operating income
-
-
1,53 mjd
-241,00 m
EBT including unusual items
37,03 mjd
33,80 mjd
25,52 mjd
34,18 mjd
EBT excluding unusual items
37,03 mjd
33,80 mjd
35,09 mjd
37,62 mjd
Income tax expense
8,00 mjd
7,30 mjd
5,51 mjd
7,29 mjd
Effective tax rate
21,60%
21,60%
21,60%
21,34%
Other operating expenses
-14,00 m
23,00 m
-
-81,00 m
Net income
29,03 mjd
26,50 mjd
20,01 mjd
26,89 mjd
Net profit margin
37,18%
34,48%
26,68%
33,98%
Earnings per share
6,53
5,96
4,50
6,04
Interest and investment income
3,42 mjd
5,31 mjd
307,00 m
4,41 mjd
Interest expense
-3,86 mjd
-4,96 mjd
-
-4,97 mjd
Net interest expenses
-433,00 m
356,00 m
307,00 m
-560,00 m
Depreciation and amortization charges
-
-
-
-
EBITDA
42,62 mjd
37,65 mjd
36,49 mjd
36,66 mjd
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer